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Background: The role of tumor necrosis factor alpha (TNF-α) in cancer is complex with both apoptotic and
anti-apoptotic roles proposed. However the mechanism is not clear. In the study, we designed to investigate the
effect of TNF-α on the activation and expression of nuclear factor kappa B (NF-κB)/p65/SLUG/PUMA/Bcl-2 levels in
human lung cancer A549 cell line, and in conditions of TNF-α-induced apoptosis.
Methods: We have engineered three A549 cell lines that were transiently transfected with PUMA siRNA, SLUG
siRNA and Bcl-2 siRNA, respectively. We have measured the in vitro effects of siRNA on apoptosis, and sensitivity to
20 ng/ml of TNF-α treatment for 24–48 h.
Results: We found the NF-κB activity and PUMA mRNA/protein was significantly increased after treatment of TNF-α
for 24 h in untreated A549 cells, and led to a significant increase in TNF-α-induced apoptosis, no significant increase
of SLUG and Bcl-2 level was shown. However, after treatment of TNF-α for 48 h in untreated A549 cells, SLUG and
Bcl-2 level was significant increased, and PUMA level was significant decreased, and TNF-α-induced apoptosis was
significantly decreased compared to the apoptosis level after treatment of TNF-α for 24 h. Inhibition of the NF-κB
activity could effectively decrease the PUMA level and increase the SLUG and Bcl-2 level. PUMA silencing by siRNA
led to a significant decrease in TNF-α-induced apoptosis after treatment of TNF-α for 24 h. Bcl-2 and SLUG silencing
by siRNA led to a significant increase in TNF-α-induced apoptosis for 48 h. Furthermore, SLUG silencing increased
PUMA level and decreased Bcl-2 level.
Conclusions: The findings suggested that TNF-α treatment promoted apoptosis via the NF-κB-dependent PUMA
pathway. The anti-apoptotic role of TNF-α was via NF-κB-dependent SLUG and Bcl-2 pathway at a later time.
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TNF-α[GenBank:AAN76506] is a potent pleiotropic cyto-
kine and is a major mediator of inflammation with mul-
tiple biological functions [1]. Several cancer therapies
exploiting the cytotoxic effect of TNF-α on solid tumors
and soft-tissue sarcomas have recently been examined in
clinical trials [2,3]. TNF-α stimulates inflammation by
turning on gene transcription through signaling cascades,* Correspondence: qdwangyaopeng@yahoo.cn
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reproduction in any medium, provided the orsuch as the nuclear factor-kappa B (NF-κB)[GenBank:
AAA20684] pathway [4]. This signaling also serves as the
primary mechanism to protect cells against apoptotic stim-
uli [5,6]. In contrast, transcription factor NF-κB can also
promote apoptosis in response to TNF-α through the acti-
vation of p53 upregulated modulator of apoptosis (PUMA)
[GenBank:AAO16862] [7]. From these observations, it is
possible to say that TNF-α has two different signaling
pathways that contradict each other. The cytotoxic effect
of TNF-α might be determined by ratios between the
apoptosis-inducing and the apoptosis-inhibiting effects.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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B-cell CLL/lymphoma-2 (Bcl-2)[NCBI Reference Sequence:
NR073605] family member. It is induced by p53 following
exposure to DNA-damaging agents, such as γ-irradiation
and commonly used chemotherapeutic drugs [7-9]. It is
also activated by a variety of nongenotoxic stimuli inde-
pendent of p53, such as serum starvation, kinase inhibi-
tors, glucocorticoids, endoplasmic reticulum stress, and
ischemia/reperfusion [10,11]. The pro-apoptotic func-
tion of PUMA is mediated by its interactions with anti-
apoptotic Bcl-2 family members [12], which lead to
mitochondrial dysfunction and caspase activation [13].
It has been reported that TNF-α-induced apoptosis is
through the NF-κB-dependent PUMA pathway in colon
cancer cells [7]. Simultaneous induction of the anti-
apoptotic NF-κB targets by TNF-α, such as Bcl-2 and
Bcl-extra large (Bcl-XL) was the cause of inhibition of
the pro-apoptotic effect of PUMA [7].
However, in breast cancer, TNF-α resistance was also
associated with SLUG[GenBank:GJ062364] upregulation
[14]. In lung cancer, SLUG confers resistance to the epi-
dermal growth factor receptor tyrosine kinase inhibitor
[15]. SLUG, a snail family transcription factor, is also a
suppressor of PUMA, which has been shown to be
involved in the control of apoptosis and resistance of
various cells to irradiation and chemotherapies [16-21].
However, knockdown of SLUG could effectively sensitize
the cells to the stimulars above through PUMA upregu-
lation [18-22]. Except for PUMA, SLUG downregulation
facilitates apoptosis induced by pro-apoptotic drugs in
neuroblastoma cells by downregulation of Bcl-2 proto-
typic anti-apoptotic protein [22]. We therefore suggested
that SLUG plays an important role in the regulation of
Bcl-2 and PUMA, by which to regulate the apoptotic
effect. Storci et al. have shown that TNF-α upregulates
SLUG via the NF-κB/HIF1alpha axis, which imparts
breast cancer cells with a stem cell-like phenotype [23].
We therefore suggest that a significant relationship
exists between NF-κB activation and SLUG/PUMA/
Bcl-2.
Lung cancer is the most frequently occurring cancer
in the world and causes more deaths in China. Despite
advances in treatment modalities including radiation,
surgery and chemotherapy, the overall survival in lung
cancer remains low. TNF-α has been shown to regulate
both apoptotic and anti-apoptotic pathways. In the
present study, we investigated the effect of TNF-α on
apoptosis in lung cancer A549 cells, and explored its
mechanism. We demonstrated that TNF-α treatment
promoted apoptosis via the NF-κB-dependent PUMA
pathway at an early time. The anti-apoptotic role of
TNF-α was via the Bcl-2 upregulation and PUMA down-
regulation by NF-κB-dependent SLUG upregulation at a
later time.Methods
Cell culture and antibodies
The human non-small cell lung cancer (NSCLC) cell line
A549 was obtained from the American Type Culture
Collection, and cultured in DMEM supplemented with
10% fetal bovine serum (FBS) and 100 IU/ml penicillin/
streptomycin in a 37°C humidified incubator with 5%
CO2. The inhibitor of nuclear factor kappa-B (IKK),
wedelolactone, was obtained from Alexis Biochemical
(Alexis Biochemical, Paris, France). Recombinant human
TNF-α was from R&D Systems (Minneapolis, MN,
USA). Antibodies for p65/PUMA/SLUG/Bcl-2/goat anti-
rabbit IgG-HRP/goat anti-mouse IgG-HRP are from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
β-actin antibody were purchased from Sigma (Sigma-
Aldrich, Shanghai, China), and Lamin A antibody from
Abcam (Cambridge, MA, USA).
siRNA transfection
Transfection was performed with Lipofectamine 2000
(Invitrogen, California, USA) following the manufacturer’s
instructions. siRNA transfection was performed 24 h
before 20 ng of TNF-α treatment. siRNA duplexes, in-
cluding PUMA siRNA, SLUG siRNA and Bcl-2 siRNA
and the control scrambled siRNA were from Santa Cruz
Biotechnology.
TNF-α treatment
Cells were plated in 12-well plates at 20 to 30% density
24 h before treatment. Human TNF-α (20 ng) was diluted
with appropriate cell culture media. In some experiments,
cells were pretreated with 25 μM of the IKK inhibitor,
wedelolactone, for 12 h before addition of 20 ng of TNF-α.
RT-PCR analysis
Total RNA was extracted from cultured cells with Isogen
(Nippon Gene, Tokyo, Japan) according to the manufac-
turer’s instructions. Random-primer, first strand cDNA was
generated from 0.5 μg total RNA with a Takara RNA PCR
kit (Takara, Japan), and the PCR analysis was performed
using gene-specific primers and first strand cDNA as the
template. The sequence of primers was as follows: SLUG,
50-gacacacatacagtgattatt-30 and 50-aaacttttcagcttcaatggc-30;
PUMA, 50-cgacctcaacgcacagtacga-30, and 50-aggcacctaattggg
ctccat-30; Bcl-2, 50-cgacgacttctcccgccgctaccgc-30; reverse, 50-
ccgcatgctggggccgtacagttcc-30; GAPDH, 50-acatcgctcagacacc
atgg-30 and 50-gtagttgaggtcaatgaaggg-30. The PCR pro-
ducts were fractionated on a 2% agarose gel and visua-
lized after ethidium bromide staining. After 3 minutes
at a temperature of 95°C, the experimental reaction
consisting of 30 cycles at 95°C for 30 s, 58°C for 60 s,
and 72°C for 30 s, and the PCR products were analyzed
by gel electrophoresis. The relative expression of mRNA
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by gene expression analysis software.
Western blot analysis
Cytoplasmic and nuclear fractions from cells were pre-
pared using the NE-PER nuclear and cytoplasmic Ex-
traction kit (Thermo scientific Pierce, Rockford, IL,
USA). Cells were lysed with RIPA buffer (150 mM NaCl,
1.0% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris, pH 8.0) containing protease inhibitor
cocktail (Roche Applied Science, Mannheim, Germany)
and 2 mM sodium vanadate. Protein concentration was
determined by BCA protein assay reagent kit (Pierce).
Equal amounts of cell lysates were separated by 10%
SDS-PAGE, electrophoretically transferred to nitrocellu-
lose membrane (Pall, Pensacola, FL, USA), immuno-
blotted with primary antibody against p-p65/P65/SLUG/
PUMA/Bcl-2/β-actin. Blots were visualized with anti-
rabbit or anti-mouse IgG conjugated with horseradish
peroxidase (HRP) and ECL reagents (Pierce).
Electrophoretic mobility shift assay
Cell extracts were prepared using a commercially available
nuclear extraction kit according to the manufacturer’s
protocol (Pierce). Electrophoretic mobility shift assay was
performed according to the provided protocol (Promega,
Madison, WI, USA). In brief, a 21-mer oligonucleotide
corresponding to the consensus NF-κB site (Promega) was
radiolabeled with (γ-32P)-ATP by aT4 kinase reaction.
Nucleotides were purified by chromatography through a
G-25 spin column (Roche Diagnostics Co. West Sussex,
UK) equilibrated in TE buffer. Ten micrograms of nuclear
protein extract were incubated with the radiolabeled
NF-κB oligonucleotide for 20 minutes at room temper-
ature. For competition studies, a 50-fold molar excess
of unlabeled oligonucleotide was added to the reaction
(a 21-mer corresponding to the AP-1 consensus sequence
(Promega) was used to confirm specificity). DNA protein
complexes were separated by electrophoresis through a
nondenaturing 4% polyacrylamide gel in 0.5 × TBE at 100
V for 2.5 h. Autoradiographic films were developed after
18 h of exposure to the gels (−20°C).
Fluorescence-activated cell sorting (FACS) analysis
To identify the induction of apoptosis, treated cells under-
went propidium iodide (PI) staining and FACS as to the
manufacture’s instruction. In brief, cells were plated at a
density of 1 × 105 cells/ml. After allowing 24 h for cell
adherence, cells were transfected and/or treated. Cells
were collected by gentle trypsinization, washed in PBS,
pelleted by centrifugation and fixed in 70% ethanol. Imme-
diately prior to staining, cells were washed twice in PBS
and resuspended in PBS containing RNase (20 μg/ml).
Cells were stained with PI (final concentration 10 μg/ml)for 10 minutes at room temperature. Samples were ana-
lyzed by FACS (FL-3 channel) using a Beckman Coulter
Counter Epics XL flow cytometer (Beckman Coulter,
Miami, FL, USA). For each sample, 50,000 events were col-
lected and stored for subsequent analysis using EXPO soft-
ware (version 2.0; Applied Cytometry Systems, Sheffield,
UK). The percentage of cells in the sub-G0 phase was
quantitated as an estimate of cells undergoing apoptosis.
Statistical analysis
All statistical analyses were performed using the SPSS10.0
software. The results were presented as means ± SD of
three replicate assays. Differences between groups were
assessed using analysis of variance (ANOVA) or the
Dunnett t-test. A P-value < 0.05 was considered to indi-
cate statistical significance.
Results
TNF-α treatment of A549 cells upregulates SLUG with a
dependency on NF-κB activation
Treatment with 20 ng/ml of TNF-α significantly stimu-
lated NF-κB transactivation function as determined by
the electrophoretic mobility shift assay (Figure 1A). The
induction of NF-κB activity was increased 8 h after treat-
ment, with the peak level of NF-κB activity at 16 h. The
stimulation of NF-κB appeared to decrease after 16 h of
treatment with TNF-α. To determine the role of SLUG
in TNF-α-induced apoptosis, lung cancer cells were trea-
ted with 20 ng/ml of TNF-α. Both SLUG mRNA and
protein were induced by TNF-α within several hours,
with the peak level of SLUG mRNA induction at 24 h
(Figure 1B), and that of protein at 48 h (Figure 1C). To
determine whether NF-κB activation is involved in SLUG
induction, lung cancer cells were pretreated with the
pharmacological IKK inhibitor, wedelolactone, then trea-
ted with TNF-α. Induction of SLUG mRNA and protein
was significantly inhibited (Figure 1D and E). The result
indicated TNF-α treatment resulted in SLUG induction in
lung cancer cell lines via NF-κB activation.
TNF-α treatment of A549 cells upregulates Bcl-2 is
dependent on NF-κB-dependent-SLUG
Treatment with 20 ng/ml of TNF-α significantly induced
Bcl-2 mRNA at 24 h (Figure 2A), and Bcl-2 protein at
48 h (Figure 2B), as with SLUG. To determine whether
NF-κB-dependent SLUG upregulation is necessary for
the induction of Bcl-2 by TNF-α, we used pharmaco-
logical IKK inhibitor, wedelolactone, which is responsible
for NF-κB activation. Wedelolactone pretreatment abro-
gated IκBα phosphorylation and degradation following
TNF-α treatment, and suppressed subsequent SLUG and
Bcl-2 induction and p65 nuclear translocation (Figure 2C
and D). Furthermore, pretreatment with SLUG siRNA
following TNF-α treatment significantly inhibited Bcl-2
Figure 1 Effect of TNF-α on nuclear factor kappa B (NF-κB) and SLUG expression. Lung cancer cells were treated with 20 ng/ml TNF-α. NF-κB
transactivation function was determined by electrophoretic mobility shift assay. SLUG mRNA and protein at different time points after
treatment were analyzed by reverse transcription PCR(RT-PCR) and western blotting, respectively. (A) NF-κB transactivation function was
determined by electrophoretic mobility shift assay at different time points after TNF-α treatment. (B) Time course of SLUG mRNA induction by
TNF-α in A549 lung cancer cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was a control. (C) Time course of SLUG mRNA
induction with or without TNF-α/wedelolactone in A549 lung cancer cells. GAPDH was a control. (D) Time course of SLUG protein induction
by TNF-α in A549 cells. Phospho-p65 and β-actin were also analyzed. (E) Time course of SLUG and phospho-p65 protein induction with or
without TNF-α/wedelolactone in A549 lung cancer cells.
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Figure 2 Effect of TNF-α on Bcl-2 expression. Lung cancer cells were treated with 20 ng/ml TNF-α. (A) Time course of Bcl-2 mRNA induction
by TNF-α in A549 lung cancer cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was loaded as control. (B) Western blot analysis of Bcl-2
protein expression in A549 cells followed TNF-α treatment for different times. (C) Wedelolactone-pretreated A549 lung cancer cells were transfected
with SLUG or the control scrambled siRNA, and then treated with TNF-α for 48 h. SLUG, Bcl-2 and p-P65 expression was analyzed by western blot.
(D) Wedelolactone-pretreated A549 lung cancer cells were transfected with SLUG or the control scrambled siRNA, and then treated with TNF-α for
24 h. SLUG, Bcl-2 and p-P65 expression was analyzed by reverse transcription PCR.
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cate that SLUG-dependent induction of Bcl-2 by TNF-α is
mediated by NF-κB activation.
TNF-α treatment of A549 cells upregulation of PUMA is
dependent on NF-κB activation
A549 cells were treated with 20 ng/ml of TNF-α. Both
PUMA mRNA and protein were induced by TNF-α within
several hours, with the peak level of PUMA mRNA induc-
tion at 12 h (Figure 3A), and that of protein at 24 h
(Figure 3B). A significant decrease in PUMA protein was
found at 48 h with 20 ng/ml of TNF-α treatment (data not
show). To determine whether NF-κB is necessary for the
induction of PUMA by TNF-α, we used wedelolactone to
inhibit NF-κB activation. Following downregulation of
NF-κB activity, PUMA was blocked with TNF-α treat-
ment. The above data indicate that induction of PUMA by
TNF-α is mediated by p65 through the canonical NF-κB
pathway.
TNF-α treatment of A549 cells induces apoptosis with a
dependency on PUMA activation
Thirty percent of apoptosis was detected in lung cancer
cells following 20 ng/ml of TNF-α treatment for 24 h
(Figure 4). However, for 48 h treatment, the apoptosis
rate reduced to 10% (Figure 4). Wedelolactone pretreat-
ment or knockdown of PUMA by siRNA led to a signifi-
cant decrease in TNF-α-induced apoptosis for 24 h
(Figure 4, *P > 0.05, **P < 0.01). The results suggest thatFigure 3 Effect of TNF-α on p53 upregulated modulator of apoptosis
mRNA expression in A549 cells following TNF-α treatment. (B) Time course
PUMA protein by TNF-α or wedelolactone treatment for different times.NF-κB-mediated PUMA induction represents a novel
mechanism mediating TNF-α-induced apoptosis.
SLUG silencing of A549 cells increases TNF-α-induced
apoptosis via PUMA activation
Thirty percent of apoptosis was detected in lung cancer
cells following 20 ng/ml of TNF-α treatment for 24 h.
However, only a low level (< 10%) of apoptosis was
detected in lung cancer cells following TNF-α treatment
at 48 h. This might be due to simultaneous induction of
the anti-apoptotic NF-κB targets by TNF-α, such as
SLUG and Bcl-2 at 48 h (Figure 1 and 2), in addition to
PUMA. In Figure 1 both SLUG mRNA and protein were
induced by TNF-α within several hours, with the peak
level of SLUG mRNA induction at 24 h (Figure 1), and
that of protein at 48 h (Figure 1). Indeed, knockdown of
SLUG by siRNA led to a significant increase in TNF-α-
induced apoptosis (Figure 4, *P > 0.05, **P < 0.01). Our
study demonstrated that SLUG silencing promoted PUMA
expression induced by TNF-α (Figure 5). The results sug-
gest that a low level (< 20%) of apoptosis at 48 h was in
part due to SLUG upregulation, which suppressed the
PUMA upregulation of TNF-α induced apoptosis.
SLUG silencing of A549 cells increases TNF-α-induced
apoptosis via Bcl-2 inactivation
In addition to PUMA, anti-apoptotic Bcl-2 was also
upregulated with TNF-α treatment. Knockdown of Bcl-2
by siRNA also led to a significant increase in TNF-α-(PUMA) expression. (A) Reverse transciption PCR analysis of PUMA
of PUMA protein induction by TNF-α in A549 cells. (C) Induction of
Figure 4 Effect of p53 upregulated modulator of apoptosis (PUMA), Bcl-2 and SLUG on apoptosis of TNF-α-induced apoptosis.
Apoptpsis of A549 cells following TNF-α treatment were analyzed after treated with wedelolactone, PUMA, bcl-2 or SLUG siRNA.
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that Bcl-2 is the major survival factor in lung cancer
cells. These results suggest that overexpression of Bcl-2
can compromise TNF-α-induced and PUMA-mediated
apoptosis (Figure 4, *P > 0.05, **P < 0.01).
Discussion
The role of TNF-α in cancer is complex with both apop-
totic and anti-apoptotic roles proposed. In this study, we
have shown TNF-α promoted apoptosis in vitro in A549
cells for 24 h, and inhibited apoptosis in A549 cells for
48 h.
Following TNF-α treatment of 20 ng/ml for 24 h, we
have detected 30% of apoptosis in lung cancer A549
cells, during which, NF-κB transactivation function was
significantly stimulated. Simultaneous induction of the
pro-apoptotic PUMA mRNA/protein was also found,
and the induction of PUMA by TNF-α is mediated by
p65 through the canonical NF-κB pathway. Otherwise,
wedelolactone pretreatment to inhibit NF-κB activity or
knockdown of PUMA by siRNA led to a significant de-
crease in TNF-α-induced apoptosis for 24 h, which was
consequent to Wang’s report [7]. Our study suggested
TNF-α treatment promotes apoptosis through the NF-
κB-dependent PUMA pathway at an early time in lungFigure 5 PUMA expression was analyzed by SLUG siRNA treatment focancer A549 cells. Activation of NF-κB is known to ren-
der cancer cells resistant to anticancer drugs. Inhibition
of NF-κB has been explored as an attractive approach
for anticancer therapies [24]. However, our data suggest
that NF-κB inhibition can compromise PUMA induction
by inflammatory cytokines, which may be involved in
tumor suppression and be beneficial for anticancer
therapies.
TNF-α is not an effective inducer of apoptosis in cul-
tured cells, likely due to simultaneous induction of both
pro-apoptotic and anti-apoptotic proteins by NF-κB. In
the present study, TNF-α is an effective inducer of apop-
tosis in cultured A549 cells for 24 h, a phenomenon
which may be cell-specific. However, only low levels
(<10%) of apoptosis were detected in A549 cells follow-
ing TNF-α treatment for 48 h. We found the PUMA
mRNA/protein was significantly decreased after TNF-α
treatment for 48 h, and the anti-apoptotic proteins Bcl-2
and SLUG, which have been shown to be involved in the
control of apoptosis and resistance of various cells to ir-
radiation and chemotherapies was significantly increased
[16-21].
SLUG, a member of the snail superfamily of zinc finger
transcription factors, is the key epithelial-mesenchymal tran-
sition (EMT) regulator responsible for conferring acquiredllowing TNF-α treatment.
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studies showed that the expression of SLUG promotes the
invasivity of lung cancer cells through increased activity of
metalloproteinase-2 and suppression of E-cadherin [26]. A
recent report suggested transfection of c-Kit in parental
multiple myeloma (MM) cells in the presence of stem cell
factor (SCF) up-regulated SLUG and increased resistance
to the chemotherapeutic agents. Moreover, MM cells
expressing SLUG showed a similar increased resistance to
the chemotherapeutic agents [27]. Vitali et al. had sug-
gested that reducing the expression of SLUG enhanced
the sensitivity of neuroblastoma cell lines to imatinib
mesylat by attenuating Bcl-2 expression [22]. SLUG can
also antagonize p53-mediated apoptosis in hematopoietic
progenitors by repressing PUMA [17]. It has been reported
that knockdown of SLUG sensitizes cancer cells to irradi-
ation and Cisplatin by PUMA upregulation [18,19]. Fur-
thermore, knockdown of SLUG could effectively sensitize
the cells to the stimulars above through PUMA upregula-
tion [18-22]. Thus, SLUG could regulate cancer cell sur-
vival via direct or indirect transcriptional regulation of pro-
apoptotic and anti-apoptotic genes, although further study
will be required to resolve the molecular details.
Our study showed TNF-α treatment for 48 h promoted
SLUG and Bcl-2 levels and decreased PUMA levels fol-
lowed by decreased apoptosis in A549 cells. After siRNA
knockdown of SLUG or Bcl-2, apoptosis of TNF-α-induced
for 48 h was significantly increased. Otherwise, knockdown
of SLUG significantly upregulated the PUMA level and
decreased the Bcl-2 level. We therefore suggest that TNF-α
treatment for 48 h increased the NF-κB-dependent SLUG
upregulation, by which PUMA was inhibited and Bcl-2 level
promoted, and then inhibited the apoptosis in A549 cells.Conclusions
We demonstrated that PUMA is a target of NF-κB and a
critical mediator of TNF-α-induced apoptosis. At an early
time, TNF-α treatment induced apoptosis by PUMA activ-
ity. At a later time, TNF-α-induced apoptosis was inhibited
by NF-κB-dependent SLUG upregulation, which suppressed
PUMA and increased Bcl-2 activity.Abbreviations
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